These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19941432)

  • 1. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.
    Postma MJ; Milne G; Nelson EA; Pyenson B; Basili M; Coker R; Oxford J; Garrison LP;
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1431-9. PubMed ID: 21133667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of prophylaxis and treatment of influenza].
    Rychlik R; Heinen-Kammerer T; Rusche H; Piercy J; Scuffham P; Zöllner Y
    Dtsch Med Wochenschr; 2003 Oct; 128(43):2267-70. PubMed ID: 14574642
    [No Abstract]   [Full Text] [Related]  

  • 4. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
    Lugnér AK; Mylius SD; Wallinga J
    Health Econ; 2010 May; 19(5):518-31. PubMed ID: 19382106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
    Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
    J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of stockpiling for an influenza pandemic.
    Dhankhar P; Dasbach EJ; Elbasha EH
    Lancet Infect Dis; 2009 Aug; 9(8):459-60. PubMed ID: 19628168
    [No Abstract]   [Full Text] [Related]  

  • 7. Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply.
    Medema JK; Zoellner YF; Ryan J; Palache AM
    Virus Res; 2004 Jul; 103(1-2):9-15. PubMed ID: 15163482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States.
    Perlroth DJ; Glass RJ; Davey VJ; Cannon D; Garber AM; Owens DK
    Clin Infect Dis; 2010 Jan; 50(2):165-74. PubMed ID: 20021259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the health-economic impact of the next influenza pandemic in The Netherlands.
    Hak E; Meijboom MJ; Buskens E
    Vaccine; 2006 Nov; 24(44-46):6756-60. PubMed ID: 16797797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
    Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
    Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of antiviral agents during an (impending) influenza pandemic].
    Opstelten W; van Steenbergen JE; van Essen GA; Van der Sande MA
    Ned Tijdschr Geneeskd; 2007 May; 151(18):1008-12. PubMed ID: 17508684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
    Talbird SE; Brogan AJ; Winiarski AP
    Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pandemic influenza: overview of vaccines and antiviral drugs.
    Cox MM
    Yale J Biol Med; 2005 Oct; 78(5):321-8. PubMed ID: 17132338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Containing pandemic influenza at the source.
    Longini IM; Nizam A; Xu S; Ungchusak K; Hanshaoworakul W; Cummings DA; Halloran ME
    Science; 2005 Aug; 309(5737):1083-7. PubMed ID: 16079251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing avian influenza in humans: the role of simple public health interventions.
    Bhatia R; Narain JP
    Southeast Asian J Trop Med Public Health; 2006 Nov; 37(6):1229-36. PubMed ID: 17333782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparing for the next influenza pandemic.
    van Dalen PJ; Wijdenes C
    Neth J Med; 2005 Oct; 63(9):337-8. PubMed ID: 16244379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of seasonal and pandemic influenza: prospects for control.
    Monto AS
    Clin Infect Dis; 2009 Jan; 48 Suppl 1():S20-5. PubMed ID: 19067611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendation of the Royal Academy for Medicine of Belgium to the responsible policy authorities in connection with the continually increasing threat of an outbreak of an influenza epidemic].
    Verh K Acad Geneeskd Belg; 2006; 68(2):139-50. PubMed ID: 16800243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.